CN-121987642-A - Application of 23-hydroxy betulinic acid in preparing medicine for treating breast cancer

Abstract

The invention relates to the technical field of biological medicine, and particularly discloses application of 23-hydroxy betulinic acid in preparation of a medicine for treating breast cancer, wherein the 23-hydroxy betulinic acid provided by the invention has the following molecular structural formula: 。

Inventors

• LIANG FAN
• ZHANG YU
• Lin Runling
• DONG JUNHONG
• Xue Ruicheng
• Dou Jiayao

Assignees

• 山东第二医科大学

Dates

Publication Date

20260508

Application Date

20260324

Claims (9)

1. Application of 23-hydroxy betulinic acid in preparing medicine for treating breast cancer, wherein the molecular structural formula of the 23-hydroxy betulinic acid is as follows: 。
2. 2. The use of 23-hydroxy betulinic acid according to claim 1 for the manufacture of a medicament for the treatment of breast cancer, wherein said medicament is for inhibiting the growth of breast cancer tumors.
3. 3. Use of 23-hydroxy betulinic acid according to claim 2 for the preparation of a medicament for the treatment of breast cancer, wherein said medicament is used for inhibiting the proliferation and/or migration invasive capacity of breast cancer cells.
4. 4. Use of 23-hydroxy betulinic acid according to claim 3 for the manufacture of a medicament for the treatment of breast cancer, wherein said medicament is used for inducing damage to breast cancer cell DNA.
5. 5. The use of 23-hydroxy betulinic acid according to claim 4 for preparing medicine for treating breast cancer, wherein the breast cancer cells are MCF-7 cells and/or MDA-MB-231 cells.
6. 6. The use of 23-hydroxy betulinic acid according to claim 1 for preparing medicine for treating breast cancer, wherein the medicine is in the form of tablet, powder, granule, capsule or injection.
7. 7. The use of 23-hydroxy betulinic acid according to claim 6 in preparing a medicament for treating breast cancer, wherein the concentration of the 23-hydroxy betulinic acid in the medicament is 4.8mg/mL to 6.3mg/mL.
8. 8. The use of 23-hydroxy betulinic acid in preparing medicine for treating breast cancer of claim 7, wherein the medicine is prepared by mixing DMSO containing 23-hydroxy betulinic acid with physiological saline until the final concentration of 23-hydroxy betulinic acid is 4.8 mg/mL-6.3 mg/mL.
9. 9. The use of 23-hydroxy betulinic acid in preparing medicine for treating breast cancer, according to claim 8, wherein the mixed volume percentage of DMSO containing 23-hydroxy betulinic acid and physiological saline is 5% DMSO containing 23-hydroxy betulinic acid+95% physiological saline.

Description

Application of 23-hydroxy betulinic acid in preparing medicine for treating breast cancer Technical Field The invention relates to the technical field of biological medicine, in particular to application of 23-hydroxy betulinic acid in preparation of a medicine for treating breast cancer. Background Breast cancer is one of the most frequently occurring malignant tumors worldwide, and constitutes a serious threat to female health in particular. Despite recent advances in chemotherapy, targeted and immunotherapy, five-year survival rates of advanced patients are still less than 30%, and development of new therapeutic strategies is highly desirable. The natural product has low toxicity and high efficiency, and has wide prospect in the research and development of anti-tumor medicaments. Therefore, it is of great significance to develop a new approach to the treatment of breast cancer based on natural products. Disclosure of Invention The invention provides an application of 23-hydroxy betulinic acid in preparing a medicament for treating breast cancer in order to develop a new way for treating breast cancer based on natural products. The 23-hydroxy betulinic acid provided by the invention can inhibit proliferation of breast cancer cells and further inhibit tumor growth by activating a p53 signal pathway and inhibiting activity of a cell cycle regulatory pathway. The invention also provides an application of the 23-hydroxy betulinic acid in preparing a medicament for treating breast cancer, wherein the molecular structural formula of the 23-hydroxy betulinic acid is as follows: 。 The 23-hydroxy betulinic acid provided by the invention can inhibit proliferation and migration invasion capacity of breast cancer cells by activating a p53 signal channel and inhibiting activity of a cell cycle regulation channel, induce damage of breast cancer cell DNA and further inhibit growth of tumors. Further, the medicament is for inhibiting the growth of breast cancer tumors. Further, the medicament is for inhibiting proliferation and/or migration invasive capacity of breast cancer cells. Further, the medicament is used for inducing damage to breast cancer cell DNA. Further, the breast cancer cells are MCF-7 cells and/or MDA-MB-231 cells. Further, the dosage form of the medicament for in vivo experiments is a tablet, powder, granule, capsule or injection. Further, the concentration of the 23-hydroxy betulinic acid in the medicine for in vivo experiments is 4.8 mg/mL-6.3 mg/mL. Further, the medicine is obtained by uniformly mixing DMSO containing 23-hydroxy betulinic acid with physiological saline until the final concentration of the 23-hydroxy betulinic acid is 4.8 mg/mL-6.3 mg/mL. Further, the volume percent of the mixture of DMSO containing 23-hydroxy betulinic acid and physiological saline is 5 percent of DMSO containing 23-hydroxy betulinic acid and 95 percent of physiological saline. The invention also provides a medicine for treating breast cancer, which is prepared by uniformly mixing DMSO containing 23-hydroxy betulinic acid and physiological saline according to volume percent of 5% DMSO+95% physiological saline until the final concentration of the 23-hydroxy betulinic acid is 4.8 mg/mL-6.3 mg/mL. Compared with the prior art, the invention has the beneficial effects that: The 23-hydroxy betulinic acid provided by the invention can inhibit proliferation of breast cancer cells and further inhibit tumor growth by activating a p53 signal pathway and inhibiting activity of a cell cycle regulatory pathway. The method comprises the following steps: The 23-hydroxy betulinic acid acts on the breast cancer xenograft tumor model, and can obviously inhibit the growth of tumors. Specifically, in the treatment process, the body weight and the mental state of the nude mice of the 23-hydroxy betulinic acid treatment group and the physiological saline treatment group are basically not different, and the tumor volume of the nude mice of the 23-hydroxy betulinic acid treatment group is obviously lower than that of the physiological saline treatment group, so that the strategy can achieve ideal treatment effect, ensure the safety of medicaments and improve the treatment rate of patients. The invention researches the change of the protein expression level of the 23-hydroxy betulinic acid acting on breast cancer cells, shows that the expression level of the P53, P21 oncostatin is obviously increased, and further inhibits the protein expression level of CYCLIND1/CDK4, thus proving that the 23-hydroxy betulinic acid can inhibit the proliferation of the breast cancer cells. The invention proves that the 23-hydroxy betulinic acid has the effect of inhibiting the proliferation of breast cancer cells in an in-vitro cell model and an in-vivo animal model of the breast cancer for the first time. It is clear that the cloning capacity and migration capacity of the breast cancer cell line can be inhibited in vitro, and the cell cycle is influenced. The